Remove Insurance Remove Pharma Remove Pharmaceutical research
article thumbnail

And so pharma profiteers again

World of DTC Marketing

This comes at a time when industry fart sniffing publications like Fierce Pharma report “pharma continues to shine under the pandemic spotlight. Pharma earned a solid No. Thus vaccine research was relatively neglected until last year – when COVID-19 suddenly became a rich country issue, and state funding poured in.

Pharma 147
article thumbnail

Entry-Level Pharma Sales: It's More Than Just a Job Search (Here's Why)

Contrarian Sales Techniques

In this blog post, I’d like to go deeper into that world, and not just finding an entry-level position in a Pharma company. Let’s look at the exciting possibilities, essential skills, and valuable resources that can prepare you for success with the entry-level pharmaceutical sales.

Sales 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharma’s ESG goals need to underscore push for health equity

Pharmaceutical Technology

On October 6, in a GlobalData webinar, experts tried to answer the question ‘ Is Pharma at an ESG turning point?’ , revealing a multitude of diverse strategies for pharmaceutical companies to remain conscious of their global impacts. GlobalData is the parent company of Pharmaceutical Technology.

article thumbnail

PhRMA is going to have to write some big checks

World of DTC Marketing

More new drugs are being developed by smaller biotechs who big pharma companies are acquiring as their drug candidates move through clinical trials. The Pharmaceutical Research and Manufacturers of America raised nearly $527 million last year and spent roughly $506 million, new tax returns obtained by OpenSecrets reveal.

article thumbnail

US Democrats’ blockbuster budget bill could spell big changes for drug prices

pharmaphorum

Chief among these provisions is that the bill will allow, and indeed require, Medicare, the US’s government-run insurance program for older Americans, to negotiate drug prices with pharmaceutical companies in some cases, something it historically has not been allowed to do.